Innovative Anti-tumor Drug R&D in China
Lecturer: Ding Jian
Professor Ding Jian is an Academician of the Chinese Academy of Engineering (CAE), Dean of the School of Pharmaceutical Sciences at the University of Chinese Academy of Sciences (UCAS), and Director of the Cancer Research Center at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
With a long-term commitment to the research and development (R&D) of innovative anticancer drugs, Professor Ding has focused on drug mechanisms of action and biomarkers, achieving remarkable accomplishments in this field. As a core developer, he has led the development and launch of the c-Met inhibitor Glumetinib in both China and Japan. Additionally, under his efforts, the third-generation EGFR inhibitor Limertinib obtained marketing approval in China in January 2025, while the marketing applications for the second-generation ALK inhibitor Foritinib Succinate and the PI3Kα inhibitor CYH33 have been officially accepted. Furthermore, 11 drug candidates have entered clinical trials, three of which are undergoing simultaneous studies in the United States, Japan, and Australia.
Professor Ding boasts an outstanding academic record: he has published more than 340 papers in high-impact journals such as Cell and Cancer Cell; he has obtained over 150 authorized invention patents worldwide; and he has been awarded more than ten major national and international honors, including two second prizes of the National Natural Science Award, one second prize of the National Science and Technology Progress Award, and the National Innovation Competition Award.
Lecture Time: 15:00–16:30, 17 October (Friday), 2025
Venue: Room 244, Huiyuan Building, Qianhu Campus, Nanchang University
Organizers: Academic Committee of Nanchang University
School of Pharmacy, Nanchang University
